During the third quarter, GDS Wealth Management trimmed its stake in UnitedHealth Group by 10.7%, offloading 5,297 shares to hold 44,252 shares valued at approximately $15.28 million as of the period’s end. Other institutional moves included LFA Lugano Financial Advisors establishing a new position worth about $25,000, Sagard Holdings adding roughly $29,000, Grey Fox Wealth Advisors allocating $33,000, and Islay Capital Management committing around $31,000. Riggs Asset Management increased its holding by 69.4%, acquiring an additional 43 shares to total 105 shares valued at $33,000. Collectively, hedge funds and institutional investors control 87.86% of UnitedHealth’s outstanding stock, underscoring the company’s appeal among large-scale asset managers.

Several Wall Street firms have reinforced bullish views on UnitedHealth without altering their buy and outperform stances. Jefferies Financial Group upgraded its recommendation to Buy and raised its future outlook, while Goldman Sachs initiated coverage with a Buy rating. UBS reiterated its Buy rating and signaled increased confidence in the company’s growth trajectory, and Mizuho maintained an Outperform position, citing favorable enrollment trends. Piper Sandler upheld an Overweight rating despite a minor technical adjustment, reflecting broad analyst conviction in UnitedHealth’s long-term prospects.

In its most recent quarterly report, UnitedHealth posted earnings per share of $2.92, surpassing consensus estimates by $0.05, on revenue of $113.16 billion, marking a 12.2% year-over-year increase. Net margin stood at 4.04%, with return on equity at 19.23%. The company declared a quarterly dividend of $2.21 per share, translating to an $8.84 annualized payout and a 2.5% yield. With a payout ratio of 46.14% and normalized free cash flow generation, the dividend appears well supported, while ongoing revenue growth across UnitedHealthcare and Optum segments provides a solid foundation for future distributions.